A cornucopia of pain conundrums and potential solutions and/or tools to help mitigate. All here, nicely packaged, randomly, in one episode of the Pain Pod! One of many more to come, in a miniseries titled: “Pain Pearls”, only here on the Pain Pod!

Come one, come all, to the Pain Pod!!!

P.S. Want to contribute or hear about a pain pearl of your own? Message Pain Guy on www.painguy.us to directly reach Mark and have your voice heard!

Pain Guy

• www.painguy.us

DVPRS (Pain Scale)

• https://www.va.gov/PAINMANAGEMENT/docs/DVPRS_2slides_and_references.pdf 

Opioid Risk Screenings

• www.opioidrisk.com 

2022 CDC Opioid Guideline Update

• Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. MMWR Recomm Rep 2022;71(No. RR-3):1–95.

Buprenorphine Induction Resources

• Kampman K and Jarvis M. American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. J Addict Med. Sep-Oct 2015;9(5):358-67.

• Ahmed, S. Bhivandkar S, et. al. Microinduction of Buprenorphine/Naloxone: A Review of the Literature. The American Journal on Addictions, 30: 305–315, 2021.

• Privia A. Randhawa, Rupinder Brar and Seonaid Nolan. Buprenorphine–naloxone “microdosing”: an alternative induction approach for the treatment of opioid use disorder in the wake of North America’s increasingly potent illicit drug market CMAJ January 20, 2020 192 (3) E73.

MOUD Minimum Durations Study

• Michael L. Dennis, Mark A. Foss, and Christy K. Scott. An Eight-Year Perspective on the Relationship Between the Duration of Abstinence and Other Aspects of Recovery. Evaluation Review 2007 31:6, 585-612